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Abstract 
The central role of platelets in acute coronary syndromes (ACS) 
and percutaneous coronary interventions (PCI) is well 
appreciated. The various platelet activation mechanisms finally 
lead to expression and activation of surface glycoprotein IIb/IIIa 
receptors that mediate platelet aggregation and thrombus 
formation. Glycoprotein IIb/IIIa inhibitors (GPIs) are the most 
potent antiplatelent agents and their role in ACS treatment and 
PCI has been dominant in the recent past. The advent of stents 
and thienopyridines minimized ischemic complications and in 
parallel the role of GPIs in low risk PCI. Despite being effective 
in decreasing PCI-related ischemic complications, the major 
drawback of GPI use is a relative increase of bleeding that can 
adversely affect prognosis. The availability of bivalirudin, which 
is regarded as an equally effective but safer antithrombotic agent 
when compared to the combination of heparin and GPIs, despite 
an ongoing controversy, has also led to a decrease of GPI use in 
PCI for ACS. Finally the advent of novel potent antiplatelet 
agents (prasugrel, ticagrelor and soon cangrelor) further 
contained GPI use in patients with ischemic – thrombotic risk 
that clearly exceeds bleeding risk and mainly for bail-out in case 
of a thrombotic event during PCI. A concise overview of 
accumulated data regarding optimal use of GPIs as determined 
by large clinical trials and recent guidelines is herein attempted. 
(Rhythmos 2016;11(2):39-48).  
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Abbreviations: ACS = acute coronary syndromes, CAD = coronary 
artery disease, GPI = glycoprotein IIb/IIIa inhibitor, MI = myocardial 
infarction, NSTE = non ST-segment elevation, PCI = percutaneous 
coronary intervention, STEMI = ST-segment elevation myocardial 
infarction   
Introduction 
The glycoprotein IIb/IIIa receptor is an integrin, a 
heterodimer consisting of αIIb and β3 subunits, which 
mediates the final common pathway of platelet aggrega-
tion. Glycoprotein IIb/IIIa inhibitors (GPIs) compete with 
fibrinogen and von Willebrand factor for glycoprotein 
IIb/IIIa binding and thus interfere with platelet cross-
linking and platelet-derived thrombus formation (Fig. 1). 
Due to this mechanism of action, GPIs are very effective 
in inhibiting platelets and 3 parenteral GPIs with different 
pharmacologic features have been approved for clinical 
use: abciximab, eptifibatide, and tirofiban (Table 1).  
 Figure 1. Schematic representation of glycoprotein IIb/IIIa 
receptors and inhibitors.  
Table 1. Pharmacologic properties of Glycoprotein IIb/IIIa 
inhibitors (GPIs) 
 Αbciximab Eptifibatide Tirofiban 
Molecule Fab 7E3 Synthetic peptide Non-peptide mimetic
Binding Non competitive Competitive Competitive 
Half-life Plasma: 10-15 h Plasma: 2-2.5 h Plasma: 2-2.5 h 
Biologic: 12 - 24 h Biologic = plasma Biologic = plasma
PCI 
dosing 
Bolus: Bolus: Bolus:
0.25 mg/kg 180 µg/kg (10 min) + 180 µg/kg 25 µg/kg 
Infusion: Infusion: Infusion:
0.125 µg/kg/min 
(12h) 
Max:10 μg/min 
2 µg/kg/min (24-48 h)  0.15 µg/kg/min (18h) 
Renal  
adjustment No 
Bolus: Bolus: 
180 µg/kg 12.5 µg/kg 
Infusion: Infusion: 
1 µg/kg/min (24 to 48 
h) 
0.075 µg/kg/min 
(18h)  
 GPIs became widely accepted into the standard of care 
for PCI during the 90’s, especially in the setting of acute 
coronary syndromes (ACS), as a strategy to reduce 
ischemic complications with a notable clinical benefit.1-4 
Although rates of short-term ischemic complications were 
as high as 10-13% in patients receiving only aspirin and 
intra-procedural heparin during PCI, the addition of GPIs 
reduced that risk by as much as 50% and long-term 
mortality by nearly 20%.3, 5 However, since platelet 
inhibition is particularly intense with GPIs, their use is 
linked to increased rates of bleeding.6, 7 Such events are 
associated with prolonged hospital stay, increased costs, 
can unfavorable impact mortality and should be prevented, 
that is why the use of GPIs has not always been broad but 
cautious and somehow limited.8, 9  
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Improvements in interventional tools (such as 
minimally thrombogenic thinner-strut stent designs) and 
pharmacotherapy (such as early administration of P2Y12 
receptor antagonists to patients with ACS and/or those 
undergoing PCI and introduction of the more potent P2Y12 
inhibitors, prasugrel and ticagrelor) have remarkably 
enhanced the safety and efficacy of PCI.10-13  Thus, 
progressively the balance of benefit versus risk with GPIs 
changed and their diminished role is reflected in current 
PCI guidelines.14 An overview of the gradual changes in 
GPI use over time, as affected by advances of 
interventional pharmacotherapy and until reaching their 
current role is attempted in this paper.   
The era before clopidogrel 
Before the era of pretreatment with clopidogrel loading 
doses, the safety and efficacy of GPIs was tested in several 
clinical studies that included patients with both ACS and 
stable coronary artery disease (CAD). EPIC was the 
landmark trial that demonstrated the efficacy of GPIs in the 
PCI setting.1 In this study, high-risk patients undergoing 
balloon angioplasty were randomized to abciximab bolus 
and infusion, abciximab bolus alone or placebo. No 
significant benefit with abciximab bolus alone was 
observed while the group treated with abciximab bolus and 
infusion had a 35% lower rate of death, myocardial 
infarction (MI), or unplanned urgent revascularization at 
30 days compared with the placebo group. Major bleeding 
complications occurred in a very high proportion of 
patients treated with abciximab.1 EPILOG was another 
landmark trial that was conducted in patients undergoing 
balloon angioplasty who were at a lower risk than the 
patients in EPIC.2 In EPILOG, abciximab was given with 
weight-adjusted infusions and was combined with lower 
doses of weight-adjusted heparin. This study showed a 
significant reduction in the incidence of death or MI in 
patients treated with abciximab with acceptable bleeding 
rates.2 Similar results were reported in the EPISTENT trial. 
which was the first randomized trial to examine the use of 
a GPI (abciximab) among patients undergoing stent 
implantation.3 The ESPRIT trial conducted in patients 
undergoing coronary stenting using eptifibatide was 
terminated early because of the superior efficacy of 
eptifibatide. Major bleeding was rare but occurred more 
frequently in eptifibatide-treated patients compared with 
placebo-treated patients.4, 15 Having the support of these 
trials, GPIs became a cornerstone in the treatment of 
patients undergoing PCI because of their ability to improve 
short- and long-term outcomes, mostly by reducing the 
occurrence of peri-procedural MI.  
The clopidogrel era 
With the advent of P2Y12 inhibitors it was suggested 
that GPIs may no longer benefit patients if they had been 
pretreated with high-dose clopidogrel, particularly those 
with stable CAD or in the absence of elevated cardiac 
enzymes. The ISAR-REACT trial showed that among 
low- to intermediate-risk patients undergoing elective PCI 
and pretreated for at least 2 hours with a 600-mg loading 
dose of clopidogrel, no benefit of abciximab therapy was 
found, compared with placebo, regarding the incidence of 
death, MI, and urgent target-vessel revascularization at 30 
days.16 The findings were similar in the ISAR-SWEET 
trial, a dedicated randomized trial to evaluate glycoprotein 
IIb/IIIa blockade in patients with diabetes scheduled for 
elective PCI.17 Overall, these two studies suggest that GPIs 
offer no clinical benefit in low- to intermediate-risk 
patients scheduled for PCI, including diabetics, in case of 
sufficient pretreatment with clopidogrel.16, 17 The ISAR-
REACT 2 trial assessed the incremental benefit of GPIs for 
patients with ACS pretreated with a high loading dose of 
600mg clopidogrel at least 2 hours before PCI. Included 
patients were randomized to either abciximab or placebo 
in the catheterization laboratory at the time of PCI. 
Abciximab reduced the incidence of the primary end point 
of death, MI, or target-vessel revascularization at 30 days, 
but the benefit of abciximab treatment was limited only to 
those patients who presented with elevated troponin.18 
Overall, these findings suggest that with high clopidogrel 
dosing regimens, GPIs should be reserved only for high-
risk patients with ACS and elevated cardiac biomarkers 
and also that these agents could be particularly useful in 
patients with substantial thrombus burden, high-risk 
anatomy, or intra-procedural complications in order to 
reduce ischemic complications of PCI.7, 18   
Timing of GPIs administration in ACS 
Two different timing strategies for the administration 
of GPIs have been used in relevant randomized trials: 
before angiography (upstream treatment) or in the cardiac 
catheterization laboratory in patients about to undergo PCI 
(provisional or downstream treatment). These two 
strategies were compared in the EARLY-ACS trial, which 
randomized 9492 invasively managed patients with non 
ST-segment elevation ACS (NSTE-ACS) to either routine 
upstream eptifibatide or placebo infusion and provisional 
eptifibatide after coronary angiography. No differences 
were found between the groups in the primary ischemic 
composite end point, while patients in the early eptifibatide 
group had significantly higher rates of bleeding and 
transfusion.7. These findings do not support the routine use 
of upstream GPIs compared with ad hoc GPIs in patients 
with NSTE-ACS undergoing PCI. 
The use of GPIs, in particular abciximab, in STEMI 
patients undergoing primary PCI is supported by a meta-
analysis of 11 randomized trials that involved a total of 
27115 patients. In this meta-analysis, the administration of 
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abciximab was associated with a significant reduction in 
the rate of re-infarction, as well as mortality rates, at 30 
days.19 However, most of the studies included in this meta-
analysis were conducted in patients who had not been 
pretreated with clopidogrel. In the BRAVE 3 study, 800 
patients with acute STEMI, all of whom were treated with 
clopidogrel 600 mg, were randomly assigned to receive 
either upstream abciximab or placebo. Abciximab was not 
associated with a reduction in the primary end point, 
infarct size, or ischemic end points at 30 days, which 
argued against the routine use of upstream abciximab in 
clopidogrel-pretreated patients undergoing primary PCI.20 
Apart from abciximab, small-molecule GPIs are also 
commonly used in clinical practice for STEMI, without 
evidence so far that would support their upstream use.21  
Strategies of facilitated PCI for STEMI have been 
developed based on the principle that time to reperfusion 
is a critical determinant of outcome.  In the FINESSE trial, 
2452 patients with STEMI who presented within 6 hours 
after symptom onset were randomized to receive PCI 
facilitated with early abciximab and half-dose reteplase 
(combination facilitated), PCI with early abciximab alone 
(abciximab facilitated) or primary PCI with abciximab at 
the time of the procedure. The primary end point 
(composite of death from all causes, ventricular fibrillation 
occurring more than 48 hours after randomization, 
cardiogenic shock, and congestive heart failure during the 
first 90 days after randomization) occurred in 9.8%, 
10.5%, and 10.7% of the patients in the combination-
facilitated, abciximab-facilitated and primary PCI groups, 
respectively (p = 0.55) without significant differences in 
mortality. These results did not support the use of a 
facilitated pharmacologic strategy for reperfusion, with 
either abciximab alone or abciximab plus reduced-dose 
reteplase, in anticipation of urgent PCI for patients who 
present early with STEMI.22  
The advent of bivalirudin and how it interferes with 
GPI use 
 Bivalirudin has been studied as an alternative to heparin 
for patients undergoing PCI with stable CAD,23, 24 NSTE-
ACS,25, 26 and STEMI.27-29 These studies found that 
bivalirudin reduced bleeding complications when 
compared with regimens of heparin plus a GPI by as much 
as 40%. However, many of these trials also found small 
numerical increases in ischemic events with bivalirudin 
and increases in acute stent thrombosis, particularly in 
patients with STEMI.27, 29 
 Data from the ACUITY trial that included 13819 
patients with NSTE-ACS randomized to heparin plus a 
GPI, bivalirudin monotherapy or bivalirudin plus a GPI, 
revealed that ischemic outcomes were similar across all 
three regimens, but bivalirudin monotherapy was 
associated with less major bleeding.25 In the HORIZONS-
AMI trial, bivalirudin monotherapy was compared with 
heparin plus GPI in 3602 patients with STEMI undergoing 
primary PCI. The composite end point of major adverse 
cardiovascular events (death, re-infarction, target vessel 
revascularization and stroke) occurred at nearly identical 
rates by 30 days in the 2 treatment arms: 5.4% with 
bivalirudin versus 5.5% with heparin plus a GPI, while 
bivalirudin was associated with a 40% reduction in major 
bleeding and a 34% reduction in 30-day mortality. These 
reductions in bleeding and mortality were found despite a 
significant increase in the risk of acute stent thrombosis 
with bivalirudin, however overall stent thrombosis rates 
did not differ in the two study groups at 30 days.27 Due to 
these two landmark trials, bivalirudin has been regarded in 
recent years as a mainstay of anticoagulation in ACS 
patients undergoing PCI, offering significant benefits in 
terms of reduced bleeding events and thus supplanted 
heparin plus GPI during PCI for many patients.  
Over time, the need for routine GPIs for PCI has 
become less evident. Two studies showed that upstream 
GPI use to treat NSTE-ACS increased the risk of bleeding 
without reducing ischemic events.7, 30 Novel potent P2Y12 
antagonists have also decreased the need for additional 
GPI use. This change of practice is reflected in current 
guidelines that recommend that GPIs should be reserved as 
bail-out therapy for thrombotic complications.14 As a 
result, there has been a need to reassess the efficacy of 
bivalirudin when compared with heparin, by conducting 
studies in which GPIs are used only on a provisional basis 
in both treatment groups.  Following the publication of 
data derived from such studies, controversies have 
emerged regarding the potential of bivalirudin to prevent 
thrombotic complications and its superior safety when 
compared with heparin alone with provisional GPI use. 
In accordance with the HORIZONS-AMI findings, the 
recently published EUROMAX trial data in patients with 
STEMI undergoing primary PCI showed that bivalirudin, 
compared with heparin with or without a GPI, significantly 
reduced the incidence of major bleeding, transfusions, and 
thrombocytopenia. Yet, in contrast with the HORIZONS-
AMI, overall cardiovascular mortality did not differ 
significantly. Acute stent thrombosis was still significantly 
higher with bivalirudin regardless of prolonged infusions 
or the use of novel P2Y12 inhibitors, whereas stent 
thrombosis rates at 30 days did not differ significantly 
between treatment arms.29 
Furthermore, according to current practices, the British 
single center HEAT-PPCI trial randomized 1812 patients 
with STEMI to receive bivalirudin or heparin.31 GPIs were 
used infrequently with bivalirudin (13%) and heparin 
(15%). In contrast with prior trials, there was no difference 
42 
 
in bleeding and bivalirudin increased the composite end 
point of death, stroke, re-infarction, or unplanned target 
lesion revascularization (8.7% vs 5.7%, p=0.01) and stent 
thrombosis (3.4% vs 0.9%, p=0.001).31  
The BRIGHT multi-center trial which was published 
most recently was more supportive for the use of 
bivalirudin.32 The trial was performed in 82 centers in 
China and randomized 2194 patients with acute MI 
undergoing PCI into 1 of 3 open-label treatment groups: 
bivalirudin and provisional GPIs, heparin and provisional 
GPIs or heparin and routine GPIs. The primary end point 
was a net adverse clinical end point (a composite of death, 
re-infarction, ischemia-driven revascularization, stroke or 
any bleeding event). Patients treated with bivalirudin and 
provisional GPIs had lower rates of this net composite end 
point (8.8%) than patients treated with either heparin and 
provisional GPIs (13.2%) or heparin and routine GPIs 
(17%). The difference between the groups was almost 
entirely driven by the difference in bleeding. There were 
no differences in ischemic events, including stent 
thrombosis. Of note, the strongest evidence supporting the 
use of bivalirudin in patients with STEMI has been the 
significant mortality reduction with bivalirudin seen in the 
HORIZONS-AMI trial. This finding was not replicated in 
BRIGHT, where there was no signal of mortality reduction 
with no difference between the bivalirudin– provisional 
GPI and the heparin–provisional GPI treatment groups.32  
 The results of HEAT-PPCI and BRIGHT are discordant 
but could be explained by the fundamental differences 
between the two trials. Firstly, the studies enrolled 
different populations since HEAT-PPCI only included 
patients with STEMI undergoing primary PCI, and 
BRIGHT randomized patients with both STEMI and 
NSTE-ACS undergoing emergency PCI. Secondly, the 
two trials significantly differed regarding the 
anticoagulation treatment. In the HEAT-PPCI trial, 
anticoagulation was initiated before arrival at the 
catheterization laboratory, whereas in the BRIGHT trial, 
anticoagulation was not administered until patients arrived 
in the catheterization laboratory. The doses of heparin to 
which bivalirudin and provisional GPIs were compared 
(70 IU/Kg in HEAT-PPCI vs 100 IU/Kg in BRIGHT) and 
the management of bivalirudin following PCI (stopped at 
the end of PCI in HEAT-PPCI with increased stent 
thrombosis vs continued for at least 30 minutes or more in 
BRIGHT without increased stent thrombosis) also 
differed. Finally, the majority of patients in HEAT-PPCI 
received novel potent platelet P2Y12 inhibitors, whereas 
these agents were not available in BRIGHT.   
 BRIGHT has been the third recently published trial 
after EUROMAX and HEAT-PPCI that has evaluated 
bivalirudin in patients with STEMI and has not been able 
to replicate the mortality reduction seen in HORIZONS-
AMI. Furthermore, in a recent meta-analysis where all of 
the trials in which bivalirudin has been compared with 
heparin were pooled (including BRIGHT), bivalirudin 
increased the risk of ischemic events, reduced the risk of 
bleeding but there was no relationship between the 
reduction in bleeding and death.33 The reduction in 
bleeding observed with bivalirudin was most apparent 
when it was compared with a regimen that included both 
heparin and a GPI. Similar results were found in a network 
meta-analysis that compared multiple anticoagulants used 
in patients with STEMI.34 In contrast, a pooled patient 
level analysis from the HORIZONS-AMI and 
EUROMAX studies found that primary PCI with 
bivalirudin improved 30-day net clinical outcomes, with 
significant reductions in cardiac mortality, major bleeding, 
transfusions and thrombocytopenia, despite increased 
acute stent thrombosis in comparison with heparin with or 
without GPI.35 However the radial approach was used only 
in 21.3% of patients, prasugrel or ticagrelor only in 18.1% 
of patients, and GPI was used in 84.8% of the control 
group, numbers that are clearly aberrant from current 
interventional practice.35. Finally, a meta-analysis (at study 
and not patient level) by Navarese et al was the largest in 
the ACS setting to evaluate the 30-day safety and efficacy 
of bivalirudin compared to heparin in conjunction with 
routine or provisional administration of a GPI.36 This 
comprehensive analysis showed that bivalirudin treatment 
resulted in a significant reduction of major bleeding as 
compared with heparin with routinely administered GPI 
but not with provisionally administered GPI. However, it 
also showed that bivalirudin compared with heparin was 
associated with a significant increase in 30-day definite 
stent thrombosis, largely driven by a greater than 4-fold 
increase in acute stent thrombosis regardless of routine or 
provisional GPI use. Moreover it demonstrated that overall 
mortality or risk of MI did not differ significantly, but 
overall revascularization rates were significantly increased 
with bivalirudin compared with heparin. Finally, in concert 
with the overall analysis, the sensitivity analyses of 
STEMI patients showed a reduction of major bleeding 
compared with heparin plus routine (but not with 
provisional) GPI and increased MI rates mainly attributed 
to increased acute (but not subacute) stent thrombosis 
compared with heparin with or without GPI.36 
In general, most recent data that followed the initial 
landmark trials in favor of bivalirudin (ACUITY and 
HORIZONS-AMI) cast some doubt about its ability to 
reduce bleeding if other bleeding prevention strategies are 
used (e.g. radial approach, heparin at 70-80 IU/kg instead 
of 100 IU/kg without GPI use and 50-60 IU/kg with GPI 
use, ACT monitoring during PCI, provisional and not 
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systematic use of GPIs with heparin).  Such doubt, 
combined with an alarming signal for increased stent 
thrombosis with bivalirudin found among several relevant 
studies and without forgetting its increased cost, may have 
already decreased its use in favor of heparin with 
provisional GPI by many interventional cardiologists.   
The advent of novel P2Y12 antagonists, prasugrel / ticagrelor 
In TRITON-TIMI 38 trial, prasugrel (an irreversible, 
but also fast-acting blocker of the P2Y12 receptor) has been 
compared to the hitherto gold standard clopidogrel among 
ACS patients with known coronary anatomy who were 
clopidogrel-naïve and was associated with significantly 
reduced rates of ischemic events with respect to a 
combined primary endpoint (cardiovascular mortality, re-
infarction and stroke), but not with an overall mortality 
advantage.13 Prasugrel has been shown to be especially 
effective in diabetic patients, high-risk patients with 
recurrent thrombotic events and in reducing stent 
thrombosis.37 The main side-effect is an increase in 
spontaneous major bleeding events (an absolute increase 
of 0.6%) compared to clopidogrel. It should be avoided in 
patients with prior stroke or transient ischemic attack, in 
patients older than 75 years and in underweight patients (< 
60 kg) which are subgroups with particularly elevated 
bleeding risk if prasugrel is administered.13  
In the PLATO trial, ticagrelor (a reversible and fast-
acting ADP-receptor blocker) has been investigated 
among ACS patients (treated primarily invasively as well 
as primarily conservatively) and shown to be superior to 
clopidogrel with respect to the same as in TRITON-TIMI 
38 combined primary endpoint (cardiovascular mortality, 
re-infarction and stroke).12 Of note, ticagrelor has 
demonstrated a significant reduction of all-cause and 
cardiovascular mortality, which was also shown in a pre-
specified subgroup analysis for diabetics and patients 
referred for coronary bypass surgery.38, 39 Potential side-
effects, besides an increase in spontaneous major bleeding 
events (an absolute increase of 0.6%), include dyspnea and 
bradycardia, both of which have been associated with the 
adenosine-like properties of the agent. 
The two above mentioned trials demonstrated the 
superiority of those two agents among patients with ACS 
and supported their upgraded status over clopidogrel in the 
most recent revascularization guidelines.14 Appropriate 
utilization of 3rd-generation P2Y12 antagonists is expected 
to attenuate the incremental benefit of GPIs in ACS with 
lower risk of bleeding and thus their availability 
contributed to a further decrease of GPI use in ACS.  
Meta-analyses & large registries assessing GPIs in ACS  
Several meta-analyses and large observational studies 
tried to answer the question of what are the benefits and 
risks when GPIs are used in patients with ACS. In a meta-
analysis of more than 30000 patients with ACS (24% of 
whom underwent PCI), Boersma et al found that treatment 
with GPIs led to a 9% reduction in the relative risk of death 
or MI with a concurrent 1% absolute increase in major 
bleeding.9 More recently, Sethi et al performed a meta-
analysis of randomized trials of GPI use in patients 
undergoing primary PCI.40 In this study of more than 7000 
patients, GPI use was associated with a 25% reduction in 
mortality. Meta-regression suggested that the benefits of 
GPIs were confined to patients at highest risk of 
mortality.40 Finally, Winchester et al performed a meta-
analysis of GPI use in ACS and PCI on the basis of trials 
performed in the contemporary era of stents and dual 
antiplatelet therapy.41 Among ACS patients, GPI use was 
associated with a significant reduction in nonfatal MI and 
an increase in minor bleeding but no differences in 
mortality or major bleeding.41 Thus, although there are 
numerous differences in patient populations, timing of 
drug administration and concomitant medical therapy, 
most studies have tended to demonstrate that GPI use in 
ACS and PCI (particularly in the highest risk patients) 
leads to modest benefits in terms of ischemic 
complications with a concomitant increase in bleeding. 
Most recently Safley et al reported the results of an 
observational study examining the efficacy and safety of 
GPI in the contemporary interventional management of 
patients with ACS.42 They performed a retrospective 
analysis of data obtained from the National Cardiovascular 
Data Registry of more than 970,000 patients undergoing 
PCI for an ACS between 2009 and 2011. About one-third 
of these patients received GPIs, and the association 
between GPI use and in-hospital mortality and major 
bleeding was assessed with three different methods of 
statistical adjustment that all resulted in very similar 
hazard ratios for the mortality and bleeding endpoints. 
Thus, GPI use was associated with reduced mortality 
(relative risk 0.72 to 0.90) and increased major bleeding 
(relative risk 1.53 to 1.93). GPIs reduced mortality in 
patients receiving heparin, but not those treated with 
bivalirudin. Despite being the most recent relevant 
publication, this study is reflective of practices between 
2009 and 2011 which differ from current ones, since only 
5-7% of patients in this cohort had radial artery access and 
only 11-12% of patients received third-generation P2Y12 
inhibitors, while results were not reported for these 
important subgroups. However, after rigorous data 
analysis, the authors validly concluded that in the modern 
PCI era there may still be a role for judicious use of GPI.42   
Current use of GPIs for PCI 
1. Stable Coronary Artery Disease (CAD) 
Recent trials did not demonstrate additional benefit 
from GPIs after a clopidogrel loading dose of 600 mg.16, 43, 
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44 Anecdotal experience, however, suggests that GPIs may 
be beneficial in bail-out situations (intra-procedural 
thrombus formation, slow flow, threatened vessel closure). 
The REPLACE-2 trial demonstrated that outcome with 
bivalirudin and provisional GPI is similar to that of heparin 
plus planned GPI during PCI for stable CAD.23 
Subsequently, ISAR-REACT 3, performed in patients pre-
treated with clopidogrel, showed similar net clinical 
outcomes to bivalirudin and heparin, but heparin dosage 
was higher (140 U/kg) than recommended, leading to an 
excess in major bleeding in patients mostly undergoing 
procedures via femoral access. In view of the primary 
endpoint results and a trend towards a lower risk of MI, 
anticoagulation with heparin with an i.v. bolus of 70 – 100 
U/kg remains the standard anticoagulant treatment for 
elective PCI. Among PCI patients with negative 
biomarkers, bivalirudin reduced bleeding without 
affecting mortality and might therefore be considered for 
use in patients at high risk for bleeding.45 
Based on the fact that recent trials could not 
demonstrate any additional benefit of GPIs after a 
clopidogrel loading dose of 600 mg, they should only be 
used in bail-out situations or at the discretion of the 
operator when PCI is performed in complex lesions.14  
2. Non-ST Elevation ACS 
In the era before dual antiplatelet therapy, trials of 
adequately dosed GPIs in patients undergoing balloon 
angioplasty and coronary stenting demonstrated a lower 
incidence of composite ischemic events in favor of GPIs in 
combination with heparin, than with heparin alone, 
primarily through a reduction in MI.9 In the ISAR-REACT 
2 trial, this benefit was maintained despite clopidogrel 
pretreatment with a loading dose of 600 mg in patients with 
non-STEMI (13.1% vs 18.3%, p=0.02), but not in those 
with unstable angina (4.6% vs 4.6%, p=0.98).18 
The ACUITY trial compared a regimen of bivalirudin 
alone (with bail-out GPI in 7.4%) against heparin plus GPI 
and found a significant benefit of bivalirudin alone with 
respect to the primary 30-day composite endpoint of 
ischemic and bleeding complications (10.1% vs. 11.7%; 
p=0.02), driven by a reduction in major bleeding 
complications (3.0% vs 5.7%, respectively; p= 0.001) 
without a significant increase in ischemic complications 
(7.8% vs 7.3%, p=0.32).25 This benefit of bivalirudin was 
found regardless of downstream or upstream GPI use and 
was maintained during 1-year follow-up.46 
The more recent ISAR-REACT 4 trial in PCI patients 
with non ST-segment elevation MI did not find a 
significant benefit of heparin with abciximab compared 
with bivalirudin alone. The primary endpoint of death, re-
infarcion, urgent target vessel revascularization, or major 
bleeding within 30 days occurred in 10.9% of patients in 
the heparin plus abciximab group, as opposed to 11% in 
the bivalirudin group (p=0.94). However, heparin plus 
abciximab was associated with significantly more major 
bleeding than bivalirudin (4.6% vs 2.6%, p=0.02).26 
Consistent with ACUITY and ISAR-REACT 4, the 
EARLY-ACS trial did not confirm a benefit in death or MI 
at 30 days from routine early versus provisional late 
eptifibatide, while routine early eptifibatide was associated 
with a higher bleeding risk (TIMI major hemorrhage 2.6% 
vs 1.8%, respectively, p=0.02).7 In TRITON-TIMI 38, 
7414 patients (54.5% of the total study population) 
received GPIs and, in terms of reducing the risk of 
cardiovascular death, MI or stroke, a consistent advantage 
was observed from prasugrel when compared with 
clopidogrel, irrespective of the use of GPIs. The risk of 
TIMI major or minor bleeding was not significantly 
different with either prasugrel or clopidogrel, regardless of 
whether or not patients were treated with GPIs.47 Overall, 
there is no evidence for an additional benefit of routine 
upstream use of a GPI in NSTE-ACS patients scheduled 
for coronary angiography and the recent guidelines 
recommend downstream GPI use in the catheterization 
laboratory for bail-out situations.14  
The use of bivalirudin preserves the option for bail-out 
glycoprotein IIb/IIIa inhibition.26 However, in lower-risk 
patients pre-treated with clopidogrel, bivalirudin does not 
appear to offer an advantage over heparin.24 It should be 
reemphasized that most of the evidence in support of 
bivalirudin is derived from trials in which the comparator 
was heparin plus GPIs, a combination that is no longer 
routinely applied. 
Ticagrelor (in all NSTE-ACS patients) and prasugrel 
(in high-risk patients referred for PCI after the coronary 
anatomy is known) are now recommended over 
clopidogrel based on the above mentioned data from 
PLATO and TRITON-TIMI 38 studies. Whether there is 
only residual benefit of GPIs with the increasing use of 
new antiplatelet agents, such as prasugrel or ticagrelor in 
NSTE-ACS, is under discussion but has not been 
addressed so far in a specific randomized controlled trial. 
3. STEMI 
Several trials, performed before the use of pre-loading 
with clopidogrel and mostly using abciximab, documented 
clinical benefits from GPIs as adjunct to primary PCI 
performed with heparin.48-51 Of note, a significant 1-year 
survival benefit was demonstrated in a meta-analysis of 
abciximab.19 With respect to the use of GPIs in acute 
STEMI patients referred for primary PCI, the best data 
exist for use of abciximab (0.25 mg/kg IV bolus followed 
by infusion of 0.125 μg/kg/min up to a maximum of 10 
μg/min for 12 h) in combination with heparin.14, 21 A meta-
analysis by Gurm et al evaluated for differences in clinical 
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outcome between small-molecule GPIs and abciximab in 
patients with STEMI undergoing primary PCI.52 Five 
randomized trials (n=2138 patients) comparing tirofiban or 
eptifibatide with abciximab as an adjunctive therapy to 
primary PCI were included. There were no differences in 
30-day mortality, re-infarction or major bleeding between 
the two adjunctive strategies.52 Thus, and according to the 
most recent guidelines for STEMI management and 
revascularization, abciximab, eptifibatide or tirofiban can 
be used in primary PCI for STEMI.14, 21 
Similar to NSTE-ACS, the upstream use of GPIs is not 
recommended in the present guidelines, because the only 
prospective randomized trial investigating the pre- vs in-
cath lab use of abciximab (FINESSE trial) was negative 
with respect to hard clinical endpoints.22 In contrast, based 
upon meta-analyses, registries, large post hoc analyses and 
the OnTIME II trial, it has been possible to demonstrate a 
benefit of early use of abciximab, particularly in patients 
that contacted rapidly the health care system (diagnosed 
and treated less than 3 hours from the onset of pain).53-57 
This is why upstream use of GPIs has regained a weak 
recommendation (IIb) in the last STEMI guidelines.21  
Although GPIs are approved for intravenous use, 
several studies have assessed the efficacy of intracoronary 
administration in patients with STEMI undergoing 
primary PCI. A meta-analysis of small-sample studies 
suggests a benefit of intracoronary use of GPIs.58 In the 
INFUSE-AMI trial, intracoronary abciximab delivered 
through a specialized drug-delivery catheter reduced 
infarct size compared with no abciximab in 452 patients 
with large, anterior STEMI undergoing primary PCI.59 
However, this finding was not supported by the large 
AIDA-STEMI trial. In this trial, a total of 2065 patients 
with STEMI undergoing primary PCI were randomly 
assigned to an intracoronary or intravenous abciximab 
bolus during the PCI procedure, followed by an 
intravenous infusion. No difference was found between 
groups in the primary end point of all-cause mortality, 
recurrent MI, or new congestive heart failure at 90 days, 
nor were there any significant differences in the secondary 
end points of early ST-segment resolution, TIMI flow 
grade, or enzymatic infarct size.60  
Based on the HORIZON-AMI study, bivalirudin 
monotherapy has been shown to be a better alternative 
compared to heparin plus GPI in patients with acute 
STEMI referred for primary PCI. Ischemic events were 
similar between both study arms, but severe bleeding 
complications were significantly reduced under 
bivalirudin.27  As a consequence, short- and long-term 
mortality was statistically reduced, which cannot be 
explained by the reduction of bleeding alone, but was the 
main trigger for a strong guideline recommendation of 
bivalirudin in this indication.14, 28 However, as analyzed 
above, this mortality benefit was not replicated in studies 
and meta-analyses that followed, while the advantages of 
bivalirudin regarding bleeding complications prevention 
seems to fade when the comparator is heparin with 
provisional and not routine GPI use and furthermore if 
most current practices with other bleeding prevention 
strategies are applied during PCI.29, 31-33, 36, 61 This is why 
in the latest revascularization guidelines, heparin plus 
planned or provisional GPI holds a class I 
recommendation, while bivalirudin holds a class IIa 
recommendation for primary PCI.14  As for patients with 
stable CAD or NSTE-ACS undergoing PCI, current 
guidelines strongly recommend the use of GPIs during 
primary PCI for STEMI for bail-out or evidence of 
thrombotic complication or no-reflow.14 An example of 
GPI use for bail-out in a primary PCI procedure for STEMI 
due to subacute stent thrombosis with massive thrombus 
burden is shown in Figures 2 and 3.   
Prasugrel and ticagrelor have replaced clopidogrel as 
the first choice therapy in STEMI.14, 21 Clopidogrel, but not 
prasugrel and ticagrelor, was used before in randomized 
studies of primary PCI for STEMI comparing bivalirudin 
to heparin with or without use of GPIs. However, like 
clopidogrel these agents also have delayed absorption in 
STEMI, and the type of P2Y12 inhibitor used did not affect 
the relative safety or efficacy profile of bivalirudin vs 
heparin with or without GPIs in the EUROMAX trial.29, 62 
With the new fast-acting and highly effective 
antiplatelet drugs such as prasugrel or ticagrelor a strategy 
of early use of GPIs seems less promising, although this 
has not been adequately investigated up to now. However, 
as recently shown, the early use of prasugrel or ticagrelor 
might not sufficiently inhibit platelet activity at the time 
when primary PCI is actually performed.62 Accordingly, 
primary PCI outcomes might be improved by 
appropriately administered IV antiplatelet therapy with 
GPIs as shown in the FABOLOUS PRO study. This study 
has shown that with prasugrel administration, the 
inhibition of platelet aggregation is suboptimal for at least 
2 hours in STEMI patients, but when given in association 
with a bolus only of tirofiban (25 μg/kg in 3 minutes), 
sufficient inhibition of platelet aggregation is obtained 
without residual variability after treatment, which makes a 
post-bolus tirofiban infusion unnecessary.63  
Cangrelor, which is expected to be available soon for 
clinical use, is an IV, potent, rapidly acting P2Y12 receptor 
inhibitor that has been evaluated in several phase III 
studies involving over 25,000 patients undergoing PCI for 
stable CAD or ACS and might prove to be a game changer.  
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 Figure 2. A case example of GPI use for bail-out due to heavy thrombus 
(procedure 1): 1. Acute MI due to subacute stent thrombosis in a 
dominant circumflex artery (LCx) just proximal to the first obtuse 
marginal branch (OM1). Five days earlier the 58-year-old male patient 
had been hospitalized because of NSTE-ACS, pretreated with aspirin 
and clopidogrel 600 mg loading dose and treated with PCI under 
bivalirudin with implantation of two stents to treat a sub-occlusive (95-
99%) lesion of the LCx at the level of the OM1. Two stents were 
implanted in the initial PCI: the first 3x15 mm was implanted directly 
in LCx (jailing the OM1 ostium) and a second 3x9 mm was added with 
minimal overlap just distally (because of edge-dissection and slow-flow 
after implanting the first), to terminate a PCI procedure without 
application of any bifurcation technique. 2-5. The patient was treated 
with multiple manual thrombectomy runs (10) that did not retrieve 
much of the massive thrombus which gradually “melted” during a long 
procedure after the administration of abciximab intracoronary bolus and 
infusion. 6. Final result: TIMI III flow was restored despite some 
residual thrombus at the bifurcation. No balloon dilation or stent 
implantation was performed. A stent visualization enhancement 
technique (StentViz) showed that the stents were well expanded, but 
with somehow irregular borders at the most proximal part. Abciximab 
infusion was continued for 12 hours, the patient was switched from 
clopidogrel to prasugrel, remained under therapeutic anticoagulation 
with enoxaparin and a new procedure under optical coherence 
tomography (OCT) guidance was scheduled 8 days later in order to 
address the issues at the LCx- OM1 bifurcation (continued in Figure 3).   
In the CHAMPION-PHOENIX trial, which included 
stable patients as well as NSTE-ACS and STEMI patients, 
cangrelor (bolus 30 mg/kg, infusion 4 mg/kg/min) 
compared to clopidogrel (loading dose of 300 mg or 600 
mg) reduced the rate of ischemic events, including stent 
thrombosis, without a significant increase in severe 
bleeding.64, 65 A pooled analysis of patient-level data from 
the 3 major cangrelor trials (CHAMPION-PCI, CHAMPION-
PLATFORM, and CHAMPION-PHOENIX) confirmed the 
lower rates of PCI peri-procedural thrombotic 
complications (3.8% for cangrelor vs 4.7% for clopidogrel, 
p=0.0007) and of stent thrombosis (0.5% vs 0.8%, 
respectively, p=0.0008) with no difference in major 
bleeding.64 These early benefits were maintained at 30 
days with consistency across all patient subgroups. There 
was no correlation between treatment effect and clinical 
presentation and there was a significant lower incidence of 
Q-wave MI in favor of cangrelor. Altogether, cangrelor 
seems to be a good therapeutic option in P2Y12 inhibitor-
naive patients undergoing PCI, although data showed no 
effect on mortality and benefits that are mainly derived 
from preventing intra-procedural stent thrombosis.64 In 
general, cangrelor, with its fast on/off effect (half-life 3 
min), seems superior to clopidogrel when preloading is not 
possible, promises rapid and sufficient inhibition of 
platelets among patients with STEMI treated with primary 
PCI, but it has so far not been compared against prasugrel, 
ticagrelor, or GPIs. Conceptually, however, it is expected 
to further challenge the GPI role in STEMI treatment.  
 Figure 3. A case example of GPI use for bail-out (continued, procedure 
2): 1. No more angiographic evidence of thrombus but severe stenosis 
remains at the OM1 ostium, which is jailed by the LCx stent. By OCT 
examination, it becomes evident that the LCx stent part proximal to the 
OM1 ostium has irregular contour and is underexpanded & undersized 
(mean diameter 2.56 mm and stent area 5.25 mm² for a 3 mm stent in 
an artery with a proximal reference diameter of 3.5 mm).  2. After 
gaining guidewire access to the OM1, a kissing balloon inflation at the 
LCx-OM1 bifurcation is performed with 3x12 mm and 2.5x12 mm non-
compliant balloons respectively. 3. A 2.5x19 mm stent is implanted at 
the ostial-proximal OM1 lesion with minimal protrusion into the LCx. 
4. A 3.5x15 mm non-compliant balloon inflation in the LCx, in front of 
the OM1 ostium, creates a mini-crush to the protruding part of the OM1 
stent. 5. Final kissing at the LCx-OM1 bifurcation with 2 non-compliant 
balloons, a 3x12 mm (LCx) and a 2.5x12 mm (OM1). 6. Optimal final 
angiographic result. At OCT control the initially irregular, 
underexpanded and undersized proximal stent part is now corrected and 
well apposed with increased mean diameter (from 2.56 mm to 3.57 mm) 
and increased lumen and stent area (from 5.25 mm² to 10.16 mm²).  
Conclusion 
GPIs provide superior protection against ischemic 
events in patients undergoing PCI for all indications and 
are particularly useful and strongly recommended in bail-
out situations and patients at high risk for ischemic events 
(Table 2). However, bleeding is undoubtedly increased 
with GPIs and alternative approaches exist. Bivalirudin is 
not less effective and holds a safety advantage over heparin 
and routine GPI, but in recently published studies it does 
not hold a clear safety advantage over heparin with 
provisional GPI use, especially when other bleeding 
prevention measures are taken, such as radial approach and 
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not very high heparin doses combined with ACT 
monitoring. It is not wise to derive a universal 
recommendation concerning the use of GPIs on the basis 
of the data. Rather, it would appear prudent to reserve GPI 
use for patients who are at high risk of early ischemic 
complications and for already heparin treated patients. On 
the other hand, in patients for whom the short-term risk of 
major bleeding is predominant, avoidance of GPIs and 
preference for bivalirudin over heparin, unless faced with 
extreme thrombotic risk, would be reasonable.   
Table 2. Situations where use of glycoprotein IIb/IIIa inhibitors 
is advocated or should be considered. 
Heavy thrombotic burden Slow flow / no-reflow 
Intra-procedural thrombus formation Threatened vessel closure
No preloading with P2Y12 antagonists Complex lesions/High risk patients 
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